A Nonprofit Seeks to Make Cell and Gene Therapies Affordable Worldwide
Cell and gene therapies are among the most promising approaches to treating diseases because they carry the potential to cure chronic and progressive conditions. The problem is that the high cost of producing these therapies, which often need to be tailored to individual patients, limits access to them, particularly in low- and middle-income countries. Caring Cross is seeking to change that through its nonprofit model that focuses on enabling hospitals and health systems to manufacture advanced therapies locally and deliver them in a cost-effective manner. We spoke to Boro Dropuli?, co-founder of Caring Cross, about how the nonprofit is seeking to lower the cost of these therapies, how it operates, and why its initially focused on HIV and sickle cell disease.?
Vice President of Technology at JPMorgan Chase & Co
3 年Boro Dropuli? Daniel Levine Challenge I see with any gene therapy, is the price it takes to conduct whole trials. Millions of dollars is unaffordable for majority. Most of the cost as I understand is for clinical trials - which involves investigators physicians etc . As I understand people eats more money rather than the drug itself . Not sure how much does local manufacturing help here! . But only way looking forward which might help is for parallel trials with similar gene therapy for same disease type .